Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • STOPDAPT-3
Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status
Posted inCardiology Internal Medicine news

Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status

Posted by MedXY By MedXY 01/18/2026
A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoagulation.
Read More
  • Long-Term Efficacy and Safety of Apremilast in Moderate to Severe Genital Psoriasis: The 32-Week DISCREET Extension Data
  • Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis
  • Bathing Frequency and Eczema Severity: Analysis of the Eczema Bathing Citizen Science Randomized Controlled Trial
  • Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
  • Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in